Brise Pharmaceuticals Announces Global License Agreement With AbbVie for Migraine Therapies
Brise Pharmaceuticals announced a global license agreement with AbbVie to advance next-generation migraine therapies.
Brise Pharmaceuticals announced a global license agreement with AbbVie to advance next-generation migraine therapies.